- Product
- Disaster subsidies must be paid to all citizens
- by Jung, Heung-Jun Apr 9, 2020 06:26am
- 9 out of 10 Dailypharm readers expressed their opinion that the government's emergency disaster aid under COVID-19 should be paid to the entire population, not just the bottom 70% of income. Dailypharm conducted an opinion poll on how to pay for emergency disaster aid through the online survey of Issue & Poll from the 1st to the 7th.
- Company
- HIRA Cancer Committee canceled and postponed again
- by Eo, Yun-Ho Apr 8, 2020 06:24am
- The talks on anticancer treatment coverage enhancement has been postponed yet again. Pharmaceutical industry sources reported the Korean health authority has canceled the Health Insurance Review and Assessment Service (HIRA) Cancer Deliberation Committee’s meeting, initially scheduled today on Apr. 8. The government agency plans to push
- COVID-19 may cause another outbreak with immunization gap
- by Lee, in-bok Apr 8, 2020 06:21am
- The National Immunization Program (NIP) for both children and adult is stepping into an alarming state as a gap in the program is widening while the COVID-19 curve has not been flattened, yet. The fear of healthcare-associated infection is surging amid the COVID-19 outbreak and many people are avoiding hospital visits as a precaution. But im
- Product
- Boots, withdraws from the pharmacy market in 3 years
- by Kim JiEun Apr 8, 2020 06:21am
- 'Boots', which opened ambitiously in Korea, claiming to be a premium health & beauty store, eventually withdrew their business after failing to overcome the continuing sluggish profitability. According to the industry on the 6th, the company recently decided to withdraw its entire business and closed the recently opened stores. In 2017,
- Policy
- GV1001 developed as a demetia drug, approved for COVID-19
- by Lee, Tak-Sun Apr 8, 2020 06:21am
- The Ministry of Food and Drug Safety approved a new drug candidate 'GV1001' by GemVax, which is being developed as a treatment for dementia, for the purpose of treating COVID-19 patients. The request for approval for the use of treatment was made by Kyungpook National University Chilgok Hospital. The MFDS approved the use of GV1001 (Ter
- Policy
- Will Rovelito by Handok & Sanofi succeed?
- by Lee, Tak-Sun Apr 7, 2020 06:44am
- Handok & Sanofi-aventis Korea are jointly developing a combination of Irbesartan & Amlodipine, which is antihypertensive drug and are expecting synergy effect between the two companies. Previously, Sanofi-aventis Korea co-developed Rovelito (Irbesartan-Atorvastatin calcium trihydrate), a new combination drug for hypertension/ hyperlipidem
- Product
- President Moon posted a memorial message on SNS
- by Kang, Shin-Kook Apr 7, 2020 06:40am
- On the 4th, President Moon Jae-in expressed his condolences to Ms. A, a medical doctor working in Gyeongsan, Gyeongbuk, infected with COVID-19. President Moon said through social networking services (SNS), "It was very sad that our infected medical staff was sacrificed for the first time while treating a COVID-19 infected patient." Mr.
- Company
- Tylenol shortage boosts Penzal sales by over 40%
- by Jung, Hye-Jin Apr 7, 2020 06:40am
- Due to the COVID-19 outbreak, acetaminophen’s top brand product Tylenol has been experiencing shortage and seemingly other alternatives are seeing a surge in sales. Chong Kun Dang Pharmaceutical official announced on Apr. 2 the sales volume of Penzal-Q in last February and March has soared over 40 percent than same time last year. And Penz
- Policy
- Samjin’s generic for Forxiga was first approved
- by Lee, Tak-Sun Apr 7, 2020 06:39am
- Samjin's SGLT-2 diabetes treatment drug 'Forxiga' was first approved. Unlike Forxiga, it is a product without solvates. Through this, it is expected to avoid the solvate patent and weigh the release around April 2023 when the material patent ends. On the 2nd, the Ministry of Food and Drug Safety approved Samjin Pharmaceutical's Dapazin
- Company
- Big5 general hospitals codes in 2nd PARP inhibitor Zejula
- by Eo, Yun-Ho Apr 6, 2020 06:28am
- The world’s second poly ADP-ribose polymerase (PARP) inhibitor Zejula’s drug code has been implemented by Big 5 general hospitals in Korea. A pharmaceutical industry source reported an ovarian cancer treatment by Takeda Pharmaceuticals Korea, Zejula (niraparib) has been registered by drug committees (DC) around 24 general hospitals so f
